Accuray showcases new long-term data¹ on benefits of 5 session radiotherapy treatment for men with prostate cancer at estro 2025

More than 40 clinical studies using accuray technology presented at estro 2025; company highlights innovation and educational symposia madison, wis. , may 7, 2025 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that new data presented at the european society for radiotherapy and oncology (estro) meeting reinforces the benefits of the company's cyberknife ® system in the treatment of prostate cancer at multiple stages of the cancer journey.
ARAY Ratings Summary
ARAY Quant Ranking